Information Provided By: 
Fly News Breaks for April 9, 2019
REGN, ALNY
Apr 9, 2019 | 07:14 EDT
BMO Capital analyst Do Kim raised his price target on Alnylam (ALNY) to $119 and kept his Outperform rating after its announced Regeneron (REGN) partnership on ocular / CNS diseases and liver-related diseases. The analyst expects the collaboration to result in favorable economics that also gives Alnylam an opportunity to co-promote its CNS program, but warns that some pressure on the stock is possible since the equity investment component by Regeneron at $90 per share was $3 below Friday's close.
News For ALNY;REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
